Cargando…
Efficacy and safety of standard of care with/without bevacizumab for platinum‐resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023
We investigated the efficacy and safety of further bevacizumab therapy in patients with platinum‐resistant ovarian cancer whose disease had progressed after bevacizumab plus chemotherapy. In this multicenter, open‐label, phase II trial (JGOG3023), patients were randomized 1:1 to a single‐agent chemo...
Autores principales: | Shoji, Tadahiro, Enomoto, Takayuki, Abe, Masakazu, Okamoto, Aikou, Nagasawa, Takayuki, Oishi, Tetsuro, Nagase, Satoru, Mori, Masahiko, Inokuchi, Yuki, Kamiura, Shoji, Komiyama, Shinichi, Takeshima, Nobuhiro, Sugiyama, Toru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748228/ https://www.ncbi.nlm.nih.gov/pubmed/34716979 http://dx.doi.org/10.1111/cas.15185 |
Ejemplares similares
-
An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
por: Shoji, Tadahiro, et al.
Publicado: (2018) -
Bevacizumab combined with platinum–taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)
por: Komiyama, Shinichi, et al.
Publicado: (2018) -
Safe administration of bevacizumab combination chemotherapy for the patients with recurrent cervical cancer after pelvic radiotherapy: Two case reports
por: Shoji, Tadahiro, et al.
Publicado: (2018) -
A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report
por: Takatori, Eriko, et al.
Publicado: (2015) -
Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 Study
por: Yoshihara, Kosuke, et al.
Publicado: (2023)